Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia

Eastern Cooperative Oncology Group362 enrolled

Overview

Phase III Study of Priming with Granulocyte-Macrophage Colony Stimulating Factor (rhu-GM-CSF) and ofThree Induction Regimens in Adult Patients (Over 55) with Acute Non-Lymphocytic Leukemia

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

362

Conditions

Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia

Interventions

GM-CSF primingDRUG

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 56 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients with acute non-lymphocytic leukemia are eligible for the study. Exclusion Criteria: * N/A

Outcomes

Primary Outcomes

complete remission rates

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.